Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 736

1.

Treatment-free remission in chronic myeloid leukemia: Floating between expectation and evidence.

Baccarani M.

Leukemia. 2017 Jan 17. doi: 10.1038/leu.2017.20. [Epub ahead of print]

PMID:
28093565
2.

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, Hoffmann VS, Gugliotta G, Hehlmann R, Hochhaus A, Hasford J, Baccarani M.

J Cancer Res Clin Oncol. 2017 Jan 12. doi: 10.1007/s00432-016-2321-2. [Epub ahead of print]

PMID:
28083711
3.

Reply to Constance et al.

Steegmann JL, Baccarani M, Clark RE.

Leukemia. 2016 Dec 6. doi: 10.1038/leu.2016.337. [Epub ahead of print] No abstract available.

PMID:
27922619
4.

Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia.

Soverini S, Baccarani M, Martinelli G.

Lancet Haematol. 2016 Dec;3(12):e554-e555. doi: 10.1016/S2352-3026(16)30170-3. No abstract available.

PMID:
27890072
5.

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

Rosti G, Castagnetti F, Gugliotta G, Baccarani M.

Nat Rev Clin Oncol. 2016 Oct 18. doi: 10.1038/nrclinonc.2016.139. [Epub ahead of print] Review.

PMID:
27752053
6.

Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.

Efficace F, Breccia M, Cottone F, Okumura I, Doro M, Riccardi F, Rosti G, Baccarani M.

Support Care Cancer. 2016 Dec;24(12):4887-4894.

PMID:
27448405
7.

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.

Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, Capodanno I, Mannina D, Salvucci M, Antolino A, Marasca R, Musso M, Crugnola M, Impera S, Trabacchi E, Musolino C, Cavazzini F, Mineo G, Tosi P, Tomaselli C, Rizzo M, Siragusa S, Fogli M, Ragionieri R, Zironi A, Soverini S, Martinelli G, Cavo M, Vigneri P, Stagno F, Rosti G, Baccarani M.

Am J Hematol. 2017 Jan;92(1):82-87. doi: 10.1002/ajh.24591.

PMID:
27770583
8.

Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.

Breccia M, Pregno P, Spallarossa P, Arboscello E, Ciceri F, Giorgi M, Grossi A, Mallardo M, Nodari S, Ottolini S, Sala C, Tortorella G, Rosti G, Pane F, Minotti G, Baccarani M.

Ann Hematol. 2016 Sep 30. [Epub ahead of print] Review.

PMID:
27686083
9.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R.

Leukemia. 2016 Sep 23. doi: 10.1038/leu.2016.246. [Epub ahead of print]

PMID:
27568522
10.

New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.

Palandri F, Auteri G, Baccarani M.

Hematol Oncol. 2016 Aug 10. doi: 10.1002/hon.2324. [Epub ahead of print] Review.

PMID:
27510853
11.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Baccarani M.

N Engl J Med. 2016 Aug 11;375(6):e9. doi: 10.1056/NEJMc1603847#SA1. No abstract available.

PMID:
27509125
12.

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients.

Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, Haluska FG.

Leuk Res. 2016 Sep;48:84-91. doi: 10.1016/j.leukres.2016.07.007.

13.

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.

Soverini S, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, Martinelli G.

BMC Cancer. 2016 Aug 2;16:572. doi: 10.1186/s12885-016-2635-0.

14.

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

Castagnetti F, Breccia M, Gugliotta G, Martino B, D'Adda M, Stagno F, Carella AM, Avanzini P, Tiribelli M, Trabacchi E, Visani G, Gobbi M, Salvucci M, Levato L, Binotto G, Capalbo SF, Bochicchio MT, Soverini S, Cavo M, Martinelli G, Alimena G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party..

Haematologica. 2016 Oct;101(10):1200-1207.

15.

Management of pregnant chronic myeloid leukemia patients.

Abruzzese E, Trawinska MM, de Fabritiis P, Baccarani M.

Expert Rev Hematol. 2016 Aug;9(8):781-91. doi: 10.1080/17474086.2016.1205479.

PMID:
27352939
16.

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A.

J Clin Oncol. 2016 Jul 10;34(20):2333-40. doi: 10.1200/JCO.2015.64.8899.

PMID:
27217448
17.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark RE.

Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Review.

18.

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW; EPIC investigators..

Lancet Oncol. 2016 May;17(5):612-21. doi: 10.1016/S1470-2045(16)00080-2.

PMID:
27083332
19.

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.

Soverini S, De Benedittis C, Polakova KM, Linhartova J, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Klamova H, Salvucci M, Crugnola M, Iurlo A, Albano F, Russo D, Rosti G, Cavo M, Baccarani M, Martinelli G.

Oncotarget. 2016 Apr 19;7(16):21982-90. doi: 10.18632/oncotarget.8010.

20.

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Gozzini A, Usala E, Carella AM, Rege-Cambrin G, Martino B, Abruzzese E, Albano F, Stagno F, Luciano L, D'Adda M, Bocchia M, Cavazzini F, Tiribelli M, Lunghi M, Pia Falcone A, Musolino C, Levato L, Venturi C, Soverini S, Cavo M, Alimena G, Pane F, Martinelli G, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party..

Am J Hematol. 2016 Jun;91(6):617-22. doi: 10.1002/ajh.24362.

PMID:
26971721
Items per page

Supplemental Content

Loading ...
Support Center